Loading
A phase 2 trial of Sutetinib Maleate Capsule in non-small-cell lung cancer, run by Teligene US, now recruiting.
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT05168566 by Teligene US, with 99 participants planned, started 2022-09-01 and due to reach its primary completion in 2027-12. Interventions recorded: Sutetinib Maleate Capsule.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.